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Fibronectin (FN) has a complex pattern of 
alternative splicing at the mRNA level. One of the al-
ternatively spliced segments, EDA, is prominently ex-
pressed during biological processes involving substan-
tial cell migration and proliferation, such as embryonic 
development, malignant transformation, and wound 
healing. To examine the function of the EDA segment, 
we overexpressed recombinant FN isoforms with or 
without EDA in CHO cells and compared their cell-
 









 FN in pro-
moting cell spreading and cell migration, irrespective of 
the presence or absence of a second alternatively spliced 





FN was not affected by antibodies recognizing the 









1 subunits and by Gly-Arg-Gly-Asp-
Ser-Pro peptide, indicating that the EDA segment en-
hanced the cell-adhesive activity of FN by potentiating 








1. In support of 

















 FN. Augmentation of 
integrin binding by the EDA segment was, however, 
observed only in the context of the intact FN molecule, 









 FN was abolished after limited 
proteolysis with thermolysin. Consistent with this ob-








1 to a recombinant 
FN fragment, consisting of the central cell-binding do-
main and the adjacent heparin-binding domain Hep2, 
was not affected by insertion of the EDA segment. 
Since the insertion of an extra type III module such as 
EDA into an array of repeated type III modules is ex-




 at the posi-
tion of the insertion, the conformation of the FN mole-
cule may be globally altered upon insertion of the EDA 





 module and/or local unfolding of the mod-
ule. Our results suggest that alternative splicing at the 
EDA exon is a novel mechanism for up-regulating inte-
grin-binding affinity of FN operating when enhanced 
migration and proliferation of cells are required.
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: CCBD, central cell-binding domain;










 are multifunctional adhesive
glycoproteins present in the extracellular matrix
and various body fluids. They provide excellent
substrates for cell adhesion and spreading, thereby pro-
moting cell migration during embryonic development,
wound healing, and tumor progression (for review see
Hynes, 1990). FNs are disulfide-bonded dimers of two
closely related subunits, each consisting of three types of
homologous repeating modules termed types I, II, and III
(Petersen et al., 1983). These repeats are organized into a
series of functional domains that bind to integrins, col-
lagens, heparin and heparan sulfate, fibrin, and FNs them-
selves.
FNs can interact with cells at three distinct regions: the
central cell-binding domain (CCBD), the COOH-terminal
heparin-binding domain (Hep2), and the type III-connect-
ing segment (IIICS) including the CS1 region (Yamada,
1991). CCBD is the major cell-adhesive domain of FN and
contains the Arg-Gly-Asp (RGD) motif that is recognized

























































1 (Ruoslahti and Pierschbacher, 1987; Hynes, 1992;








1 is the primary



















 module for binding to FN (Aota et al., 1991). Re-
cently, a short sequence Pro-His-Ser-Arg-Asn (PHSRN)


























1 with CCBD has been
shown to transduce signals that regulate cell proliferation,
differentiation, and apoptosis (Giancotti and Ruoslahti,
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1990; Meredith et al., 1993), although the molecular basis
for integrin-mediated signaling is not well understood. The








1 interaction has been
demonstrated in mice by the embryonic lethality of defi-








1 expression (George et al.,
1993; Yang et al., 1993).
FNs purified from different sources appear to be slightly
different with respect to subunit sizes (Yamada and
Kennedy, 1979). The heterogeneity of FN subunits arises
mainly from alternative splicing of a primary transcript at
three distinct regions termed EDA, EDB, and IIICS
(Schwarzbauer et al., 1983, 1987; Kornblihtt et al., 1984;
Zardi et al., 1987). The EDA and EDB segments are each
encoded by a single exon and can each comprise an intact
type III repeat (Schwarzbauer et al., 1987). The IIICS seg-
ment, on the other hand, consists of five distinct variants
due to exon subdivision (Kornblihtt et al., 1985; Sekiguchi
et al., 1986). Up to 20 different FN subunits may result
from alternative splicing involving these three segments.
Many lines of evidence indicate that alternative splicing at
these regions is regulated in a tissue-specific and oncode-
velopmental manner. For example, plasma FN produced
by adult hepatocytes contains neither EDA nor EDB seg-
ments in both subunits and lacks the entire IIICS in one of
the subunits, although cultured fibroblasts typically pro-
duce some FNs containing the EDA and/or EDB seg-
ments (Kornblihtt et al., 1984; Sekiguchi et al., 1986; Zardi
et al., 1987). FNs expressed in fetal and tumor tissues con-
tain a greater percentage of EDA and EDB segments than









; 1993; Carnemolla et al., 1989; ffrench-Constant
and Hynes, 1989). Increased expression of FNs containing
the EDA and/or EDB segments has also been observed
during wound healing (ffrench-Constant et al., 1989).
Despite accumulated evidence for regulated expression
of EDA- and/or EDB-containing FNs in vivo, the biologi-
cal functions of these isoforms are only poorly understood.
Many efforts have been made to detect functional differ-
ences between plasma FN and FNs purified from condi-
tioned medium of cultured fibroblasts, collectively re-
ferred to as “cellular FN,” and to elucidate the function of
alternatively spliced coding regions. No clear differences
have been reported, however, between plasma and cellu-
lar FNs in their abilities to promote cell adhesion and
spreading, except that these two forms differ in their solu-
bilities (for review see ffrench-Constant, 1995). Since cel-
lular FN is a mixture of heterodimers of several different
subunits differing with respect to the presence or absence
of the EDA and/or EDB segments, failure to detect func-
tional differences could be due to heterogeneity of cellular
FN. To overcome this problem, Guan et al. (1990) ex-
pressed, in mouse lymphoid cells, various recombinant iso-
forms of rat FNs, each containing a different combination
of the three alternatively spliced regions, and compared
the biological activities of the homogeneous recombinant
proteins. No clear differences were, however, observed
among the abilities of FN isoforms to promote cell adhe-
sion, spreading, and migration, except for minor differ-
ences in the ability to assemble into the preexisting extra-
cellular matrix.
Recently, we constructed an expression vector encoding
full length human plasma FN that lacks both the EDA and
 
EDB segments but includes IIICS and overexpressed this
recombinant isoform in human tumor cells to restore the
pericellular FN matrix around the tumor cells (Akamatsu
et al., 1996). In the present study, we constructed two addi-
tional expression vectors encoding human FNs containing
either both the EDA and EDB segments or the EDA seg-
ment alone and overexpressed these FN isoforms in CHO
cells to compare the biological activities of three distinct

























 FNs) using purified homodimeric









 isoform in pro-
moting cell spreading and cell migration, irrespective of
the presence or absence of the EDB segment. Increased




 FN substrate was









1. We discuss molecular mechanisms and impli-
cations of the EDA-dependent enhanced integrin binding
on the basis of conformational modulation of the FN mol-






cDNA expression vectors for the full length human FN isoforms differing
in the presence or absence of the EDA and/or EDB segments were con-
structed by modifying pAIPFN that encodes a full length FN lacking both
extra type III repeats (Akamatsu et al., 1996). pAIPFN was first modified




 to the ATG initiation codon as fol-
lows: pAIPFN was cleaved with BamHI and EcoRV and the resulting
2411-bp cDNA fragment encoding the signal sequence of human protein




-terminal FN sequence was filled in using the Klenow
fragment of DNA polymerase I and subcloned into the EcoRV site of
pBluescript II (Stratagene, La Jolla, CA). The insert was excised as 1703-bp
HindIII–SalI fragment and ligated into HindIII–SalI-cleaved pAIPFN,
yielding the expression vector (pAIFNC) for the FN isoform lacking both
the EDA and EDB segments. pAIFNC is identical to pAIPFN except for





For construction of the expression vector encoding the FN isoform con-
taining EDA but not EDB, a BamHI–XbaI fragment of pHCF5 (provided
by Dr. K. Ichihara-Tanaka, Fujita Health University, Toyoake, Japan)









was cloned into the BamHI site of pUC119 in tandem with a XbaI–













 untranslated sequence including a polyadenyla-





glutamic acid in the mature protein (Petersen et al., 1989). The whole in-
sert was then excised with BamHI and inserted into BamHI-cleaved








FN was designated pAIFNAC.
For construction of the expression vector encoding the FN isoform con-









 without the EDB segment was excised from pHCF93 (pro-
vided by Dr. K. Ichihara-Tanaka), filled in with the Klenow fragment of
DNA polymerase I, and subcloned into the HincII site of pUC119 from









 was excised from the pUC119 derivative (designated pHCFN93)
with EcoRI and SacI and ligated into EcoRI–AccI-cleaved pHCFN93 in tan-








including the EDB segment. The resulting plasmid was linearized with SacI

















 was excised with
SalI and BamHI, and ligated to SalI–BamHI-cleaved pAIFNC. The plas-
mid was then recut with BamHI and ligated with the BamHI fragment ex-




 through the SV40 polyadenyla-
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Human HT1080 fibrosarcoma cells, human WI-38 fibroblasts, rat NRK
cells, and hamster CHO-K1 cells were obtained from the Japanese Cancer
Research Resources Bank (Tokyo, Japan). Mouse L cells were provided
by Dr. Masahiro Ishiura (National Institute for Basic Biology, Okazaki,
Japan). The heparan sulfate-deficient CHO cell line 803, which expresses
5–10% of the wild-type level of heparan sulfate (Esko et al., 1988) was
provided by Dr. Shigeki Higashiyama (Osaka University Medical School,
Osaka, Japan). The dihydrofolate reductase-deficient CHO cell line,
CHO DG44, was provided by Dr. Lawrence Chasin (Columbia Univer-
sity, New York) and used for the production of recombinant FNs.
HT1080, WI-38, NRK, and L cells were grown in DME supplemented





medium containing ribonucleosides and deoxyribonucleosides (GIBCO
BRL, Gaithersburg, MD) plus 10% FBS.
 
DNA Transfection and Selection of
Stable Transfectants
 
cDNA expression vectors were cotransfected into CHO DG44 cells with
pGEMSVdhfr encoding a dehydrofolate reductase minigene (provided by
Dr. Hiroshi Teraoka, Shionogi Research Laboratory, Shionogi and Co.,
Ltd., Osaka, Japan) by the calcium-phosphate precipitation method
(Chen and Okayama, 1987). Selection of stable transfectants and subse-
quent amplification of the introduced cDNA were carried out as described
(Kaufman, 1989). Levels of recombinant FN expression were routinely
monitored by dot immunoassay of the culture supernatants with the anti–
human FN mAb FN8-12 (Matsuyama et al., 1994). Levels of recombinant




40 times higher than that of









-minimal essential medium with 1% FN-depleted FBS. FN-depleted FBS
was prepared by passing through a gelatin-affinity column twice. The cul-
ture supernatants were subjected to affinity chromatography using gela-
tin-Sepharose (Pharmacia Biotech, Uppsala, Sweden). Plasma and cellu-
lar FNs were purified as described previously (Sekiguchi et al., 1985).
Typical yields of recombinant FNs were 4–6 mg/liter of conditioned me-
dia. In some experiments, gelatin affinity-purified FNs were further puri-













1 subunits, 8F1 and 4G2, were established
in our laboratory by fusion of SP2/0 myeloma cells with the spleen cells of








1 purified from human pla-








1 to FN as well as at-
tachment and spreading of HT1080 cells on FN-coated substrata. mAbs
against human FN, 15E, and 17C were also established in our laboratory
using human plasma FN as immunogen. 15E and 17C recognize epitopes





4 subunit (SG/73; Miyake et al., 1992) and heparan sulfate
(HepSS-1) were obtained from Seikagaku Corp. (Tokyo, Japan); mAb








3 (LM609) was from Chemicon International,
Inc. (Temecula, CA); mAbs against human FN (FN8-12 and FN30-8)
were from Takara Shuzo (Kyoto, Japan); HRP-conjugated mAb against
human FN (OAL115) from Hisanobu Hirano (Otsuka Pharmaceutical
Co., Ltd., Tokushima, Japan); mAbs against EDA (IST-9; Borsi et al.,
1987) and against FN containing the EDB segment (BC-1) from Dr. Lu-
ciano Zardi (Instituto Nazionale per la Ricerca sul Cancro, Genova, Italy);
another mAb against EDA (HHS01; Hirano et al., 1992) from Eiji Sakashita
(Otsuka Pharmaceutical Factory, Inc., Tokushima, Japan). Polyclonal an-
tibody against human FN was raised in rabbits by repeated immunization
with purified human plasma FN emulsified in complete Freund’s adjuvant.
The polyclonal antibody was purified on a Sepharose affinity column con-
jugated with a recombinant CCBD fragment (Chen et al., 1996). Control
IgG, goat anti–mouse IgG, HRP-conjugated goat anti–rabbit IgG, and
FITC-conjugated goat anti-mouse IgM were from Cappel Worthington
Biochemicals (Malvern, PA). The synthetic peptides Gly-Arg-Gly-Asp-
Ser-Pro (GRGDSP) and Gly-Arg-Gly-Glu-Ser-Pro (GRGESP) were ob-
tained from Iwaki Glass Co. (Chiba, Japan).
 
MBP- and GST-Fusion Proteins
 








 modules of human FN with or
without the inserted EDA segment were amplified by reverse transcrip-
tion PCR from mRNA extracted from WI-38 human fibroblasts using for-
ward and reverse primers tagged with BamHI and SalI sites, respectively.




























 (reverse), where restriction sites and the stop codon are in-
dicated with bold and italic characters, respectively. PCR-amplified
fragments were cloned between the BamHI and SalI sites of pMAL-cRI





 as fusion proteins with maltose-binding protein (MBP). The re-
sulting fusion proteins, designated MBP11-12 and MBP11-A-12 (see Fig.
1), were purified from the bacterial lysate using amylose resin columns.
Recombinant fragments encompassing CCBD-Hep2 interval were pre-
pared as fusion proteins with glutathione-S-transferase (GST). cDNA








 modules with or without the EDA
segment were amplified by PCR from pAIFNBAC and pAIFNC, respec-





























 (reverse), where the bold and italic characters
indicate the restriction sites (SmaI and SalI) and stop codon, respectively,





human FN (Sekiguchi and Titani, 1989). cDNA fragments were cleaved
with SmaI and SalI and cloned into pGEX4T-1 (Pharmacia Biotech). The




 strain BL21, and the resulting GST
fusion proteins (designated GST-CAH and GST-CH; see Fig. 1) were pu-
rified on glutathione Sepharose columns (Pharmacia Biotech) as sug-
gested by the manufacturer, followed by ion exchange chromatography
using a HiTrapQ column. The GST fusion protein containing only CCBD,
designated GST-C, was prepared in the same manner except that the







CCGGGTCATGTTCGGTAATTAATGGAAATTG-39 as the reverse
primer.
Fragmentation of Recombinant FNs
Limited proteolysis of recombinant FNs with thermolysin was performed
as described previously (Sekiguchi et al., 1985). Briefly, recombinant FNs
(100 mg/ml) were digested with thermolysin (2.5 mg/ml) in 20 mM Tris-
HCl, pH 7.6, containing 1.9 mM CAPS, 50 mM NaCl, 0.5 mM EDTA, and
2.5 mM CaCl2 at 228C for 10 min. The digestion was terminated by addi-
tion of phosphoramidon (Peptide Institute, Minoh, Japan) to a final con-
centration of 4 mg/ml. Under these conditions, the central region of re-
combinant FNs consisting of III2–III14 modules remained mostly intact
and was obtained as 150–120-kD fragments from rFN(C) and as 160–130-
kD fragments from rFN(AC) (Sekiguchi et al., 1985). Contiguity of
CCBD and the adjacent Hep2 domain was confirmed by immunoblotting
analysis of the digests with mAbs directed to CCBD (15E) and the Hep2
domain (17C).
SDS-PAGE and Immunoblot Analysis
SDS-PAGE was performed as described by Laemmli (1970). Purified FNs
were separated on 6% polyacrylamide gels and transferred to nitrocellu-
lose membranes. The membranes were stained with mAbs against human
FN using ECL reagents (Amersham Corp., Arlington Heights, IL).
Cell Spreading Assay
Cell spreading assays were performed using 96-well microtiter plates
(Maxisorp; Nunc, Roskilde, Denmark) coated with various concentrations
of recombinant FNs and blocked with 1% BSA. Amounts of recombinant
FNs immobilized on plates were determined by ELISA using anti–human
FN antiserum or anti-FN mAbs. HT1080 cells were plated at a density of
2–3 3 104 cells/well in DME and incubated at 378C for 30 min. For inhibi-
tion assays with anti-integrin antibodies and peptides, HT1080 cells were
preincubated at 378C for 15 min in DME containing 0.2% BSA and mAbs
(10 mg/ml), synthetic peptides (1 mg/ml), or MBP fusion proteins (100
mM). The pretreated cells were dispersed by pipetting before plating. For
inhibition assays using anti-FN mAbs, the 96-well plates coated with re-
combinant FNs were incubated with mAbs (20 mg/ml) containing 0.1%
BSA at 378C for 30 min before plating of cells. After incubation for speci-
fied periods of time at 378C, nonadherent cells were removed by washing
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with DME, and attached cells were fixed with 3.7% formaldehyde and
then stained with Giemsa. Cells adopting a well spread morphology (i.e.,
cells that had become flattened with the long axis more than twice the di-
ameter of the nucleus) were counted per square millimeter.
In some experiments, recombinant FNs were immobilized onto 96-well
plates via the anti–human FN mAb FN8-12 which had been precoated on
the plates. Amounts of the recombinant FNs captured on plates were de-
termined by ELISA using the anti-FN mAb OAL115.
Treatment of Cells with Glycosidases
HT1080 cells were resuspended in DME containing 0.1% BSA at 3 3 105
cells/ml in the presence or absence of 0.1 U/ml of heparitinase I, hepari-
nase, or chondroitinase ABC (Seikagaku Corp.). Cell suspensions were
incubated for 30 min at 378C before the cell spreading assay.
Flow Cytometry
HT1080 cells were stained with the anti-heparan sulfate mAb HepSS-1
(isotype, IgM), followed by incubation with FITC-conjugated goat anti–
mouse IgM, and then analyzed using a FACScan® flow cytometer (Becton
Dickinson Immunocytometry Systems, San Jose, CA).
Purification of a5b1 and avb3 Integrins
Purification of integrin receptors and reconstitution of purified integrins
into liposomes were carried out according to Pytela et al. (1987). Briefly,
fresh human placental tissue was extracted with TBS(1) (25 mM Tris-
HCl, pH 7.5, 0.13 M NaCl, 1 mM CaCl2, and 1 mM MgCl2) containing 100
mM octylglucoside and 1 mM PMSF. The extract was applied on a series
of Sepharose affinity columns conjugated with either GRGDSPK peptide
(for purification of avb3) or the 155-kD/145-kD thermolysin fragments of
human plasma FN (for purification of a5b1). Integrins bound to these af-
finity columns were eluted with TBS(1) containing GRGDSP peptide
(250 mg/ml). Eluted integrins were further purified on a column of wheat
germ lectin Sepharose (Pharmacia Biotech). Purified integrins (50 mg)
were mixed with egg yolk phosphatidylcholine (50 mg) containing [3H]di-
palmitoyl phosphatidylcholine (New England Nuclear, Boston, MA) in
TBS(1) containing 50 mM octylglucoside and then dialyzed against
.4,000 vol of TBS(1) at 48C overnight. The reconstituted integrin lipo-
somes were size fractionated on a Sepharose CL-4B column (Pharmacia
Biotech) and used in the integrin liposome binding assay.
Integrin Liposome Binding Assay
Integrin liposomes in TBS(1) containing 0.2% BSA were added to micro-
titer wells precoated with recombinant FNs (20 mg/ml) or GST fusion
fragments (20 or 80 mg/ml) and incubated for 6 h at room temperature.
Amounts of recombinant FNs immobilized on wells were verified by
ELISA using polyclonal antibody against CCBD. For inhibition assays,
the integrin liposomes were preincubated with anti-integrin mAbs (10 mg/
ml unless otherwise specified), control IgG (20 mg/ml), or synthetic pep-
tides (1 mg/ml) for 30 min at room temperature before addition to FN- or
fusion fragment-coated wells. The wells were washed with TBS(1), and
bound liposomes were recovered in 1 N NaOH. The radioactivity of
bound liposomes was quantitated using an Aloka LSC-3500 scintillation
counter (Aloka Co., Ltd., Tokyo, Japan). In the binding assays using ther-
molysin-cleaved FNs as ligands, phosphoramidon (4 mg/ml) was included
in the assay medium to inactivate thermolysin.
Cell Migration Assay
Thin plastic discs (f 6 mm) were cut in half and coated with 0.01% poly-
l-lysine (Sigma Chemical Co., St. Louis, MO) followed by blocking with
1% BSA. Plastic discs were placed in wells of 96-well microtiter plates
that had been precoated with 5 mg/ml of recombinant FNs or 0.01% poly-
l-lysine and then blocked with 1% BSA. HT1080 cells suspended in DME
were seeded onto the plates at a density of 1 3 104 cells/well. After incu-
bation at 378C for 1.5 h, plastic discs were removed carefully, and the wells
were gently washed with DME and photographed. Cells attached to the
96-well plates were further incubated for 12 h in DME to allow them to
migrate into the open space left after removal of the discs. The cells were
then fixed with 3.7% formaldehyde and stained with Giemsa. Cell motility
was assessed by the distance of the outward migration, i.e., the distance
between the positions of the cell front before and after cell migration. The
assay was also performed in the presence of the anti-integrin a5 mAb 8F1
(20 mg/ml) or control IgG (20 mg/ml).
Results
Construction of Expression Vectors
Encoding FN Isoforms Differing in the Inclusion
of EDA and/or EDB Segments
Three human FN isoforms used in this study are illustrated
in Fig. 1. These isoforms are identical except for the pres-
ence or absence of the EDA and/or EDB segments. All
three include the complete IIICS sequence of 120 amino
acids. FN isoforms were expressed as chimeric proteins
with the signal sequence of human protein C inhibitor as
described previously (Ichihara-Tanaka et al., 1990). The
expression vectors for these isoforms were constructed by
modifying the human FN expression vector pAIPFN (Aka-
matsu et al., 1996) as described in Materials and Methods.
The resulting FN isoforms are designated as follows:
rFN(C), the isoform lacking both EDA and EDB seg-
ments; rFN(AC), the isoform containing EDA but lacking
EDB; and rFN(BAC), the isoform containing both EDA
and EDB segments.
Expression and Purification of Recombinant FNs
Expression vectors were cotransfected into CHO DG44
cells with a dihydrofolate reductase minigene, and the re-
sulting stable transfectants were treated with increasing
concentrations of methotrexate to amplify the introduced
recombinant genes. Recombinant FN isoforms were puri-
fied from the conditioned media of methotrexate-resistant
Figure 1. The structure of recombinant FNs and bacterially ex-
pressed fusion fragments. Modular structures of recombinant
FNs are shown schematically on the basis of internally homolo-
gous modules termed types I, II, and III. The EDA and EDB seg-
ments are shown with filled rectangles, while the IIICS segment is
shown by a hatched oval. All recombinant FNs contain the com-
plete IIICS sequence of 120 amino acids. Functional domains that
interact with heparin (Hep1, Hep2), fibrin (Fib1, Fib2), bacteria,
collagen, and cell surface integrins (CCBD) are indicated above
the schemes. Recombinant FN fragments encompassing different
intervals of type III modules were produced as fusion proteins
with either GST or MBP.
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transfectants by gelatin affinity chromatography. Typical
yields of recombinant FNs were 4–6 mg/liter of condi-
tioned medium. Since the concentration of hamster FN in
the conditioned medium of untransfected CHO cells was
0.1–0.15 mg/liter, the fraction of contaminating hamster
FN in the purified recombinant FNs should not exceed 4%
of total protein.
Purified FNs gave single bands with apparent molecular
masses of 220–250 kD upon SDS-PAGE under reducing
conditions (Fig. 2 A). The relative molecular masses of the
recombinant FNs were in the order of rFN(BAC) .
rFN(AC) . rFN(C), consistent size differences expected
due to the presence or absence of the EDA and/or EDB
segments. The recombinant FNs gave sharper bands in
SDS-PAGE compared to native FNs purified from plasma
(plasma FN) and from conditioned medium of cultured fi-
broblasts (cellular FN), confirming the homogeneity of the
recombinant FNs. SDS-PAGE under nonreducing condi-
tions showed that almost all of the recombinant FNs exist
as dimers, as observed for plasma and cellular FNs (Fig. 2
A). Presence or absence of the EDA and EDB segments
were confirmed by immunoblot analysis (Fig. 2 B).
Cell Adhesive Activity of Recombinant FNs
EDA1 FN isoforms have been shown to be expressed
prominently in tissues where cells actively proliferate and
migrate, such as those in embryos, tumors, and healing
wounds. To explore the physiological functions of the
EDA segment, we first compared the cell-adhesive activity
of recombinant FNs with or without EDA. When HT1080
cells were incubated on substrates coated with recombi-
nant FNs or with plasma or cellular FN, significant differ-
ences were seen in the numbers of cells attached to differ-
ent forms of FNs (Fig. 3 A). HT1080 cells attached in
greater numbers to substrates coated with rFN(AC) or
rFN(BAC) than to the substrate coated with rFN(C). A
similar but less pronounced difference was observed be-
tween the substrates coated with plasma or cellular FNs.
In addition to promoting more cell attachment, rFN(AC)
and rFN(BAC) were more potent in inducing cell spread-
ing than rFN(C) (Fig. 3 B). Similarly, cellular FN was
more active than plasma FN in inducing cell spreading, al-
though the difference between cellular and plasma FNs
was less evident than between rFN(AC) and rFN(C). No
significant difference was found, however, between rFN(AC)
and rFN(BAC), indicating that the insertion of the EDB
segment did not affect the cell spreading activity of EDA1
FN isoforms. Enhanced cell spreading onto EDA1 FN-
coated substrates was also observed with other cell lines
including rat NRK cells, mouse L cells, and hamster CHO-
K1 cells (data not shown).
The greater cell-adhesive activity of the EDA-contain-
ing isoforms was not an artifact because of variation in
quantities of FNs adsorbed onto the substrata, since equal
adsorption of FNs onto plastic surfaces was confirmed by:
(a) ELISA using different mAbs directed to conserved FN
epitopes, and (b) extraction of the substrate-bound FNs
Figure 2. SDS-PAGE and immunoblot analyses of recombinant
FNs. (A) Recombinant FNs as well as plasma and cellular FNs
(abbreviated pFN and cFN, respectively), both purified by gela-
tin-affinity chromatography and subsequent ion exchange chro-
matography on a HiTrap Q column (see Materials and Methods),
were subjected to SDS-PAGE under reducing (top gel) or nonre-
ducing (bottom gel) conditions and visualized by Coomassie
staining. 2 mg of protein was applied to each lane. Positions of the
dimeric and monomeric forms of FNs are indicated in the right
margin. Shown in the left are the positions of molecular size
markers. (B) Purified FNs (0.6 mg/lane) were subjected to SDS-
PAGE under reducing conditions followed by immunoblotting
with the following anti-FN mAbs: FN8-12 recognizing Fib2 do-
main (top panel); IST-9 recognizing the EDA segment (middle
panel); BC-1 recognizing the EDB1 FNs (bottom panel).
Figure 3. Attachment and
spreading of HT1080 cells on
FN-coated substratum. (A)
HT1080 cells (2 3 104) were
seeded on 96-well microtiter
plates coated with 5 mg/ml of
different FN isoforms and in-
cubated for 30 min at 378C.
The cells were rinsed, fixed,
and stained with Giemsa.
Bar, 100 mm. (B) Spreading
of HT1080 cells was quanti-
fied as described in Materials
and Methods. The standard
deviations of multiple deter-
minations (n 5 3) are indi-
cated at the top of bars.
The Journal of Cell Biology, Volume 139, 1997 300
with heated SDS-PAGE sample treatment buffer contain-
ing 5% 2-mercaptoethanol and subsequent SDS-PAGE
(data not shown). Furthermore, essentially identical re-
sults were obtained when FNs were indirectly immobilized
on the substratum via several different anti-FN mAbs,
each recognizing different epitopes present in all FN iso-
forms tested (data not shown).
Fig. 4 shows the dose dependence of the spreading of
HT1080 cells on different FN isoforms. The number of
spread cells reached a plateau at .10 mg/ml of recombi-
nant FNs irrespective of the presence or absence of the al-
ternatively spliced segments. rFN(AC) and rFN(BAC)
were more potent than rFN(C) in promoting cell spread-
ing throughout the range of FN concentrations examined.
A maximal difference between EDA1 and EDA2 iso-
forms was observed at 5 mg/ml recombinant protein.
EDA Segment Does Not Contain an Additional Site 
that Promotes Cell Spreading
One possibility to explain enhanced cell speading on the
EDA1 FN isoforms is that the EDA segment may contain
an additional cell-interactive site that cooperates addi-
tively or synergistically with the RGD motif in CCBD. To
explore this possibility, two types of EDA antagonists, i.e.,
mAbs directed against the EDA segment and recombi-
nant peptide containing the EDA segment, were tested for
their abilities to inhibit rFN(AC)-mediated cell spreading.
Pretreatment with two distinct anti-EDA mAbs (IST-9
and HHS01) did not inhibit cell spreading on rFN(AC) or
rFN(C), whereas the function-blocking mAbs directed
against CCBD inhibited cell spreading almost completely
on both types of FN isoforms (Fig. 5 A). Furthermore, re-
combinant peptide MBP11-A-12 containing the EDA seg-
ment failed to inhibit cell spreading onto the rFN(AC)-
coated substrates, as was the case with the control MBP
fusion protein lacking the EDA segment (Fig. 5 B). The
inability of the EDA segment to directly interact with
HT1080 cells was also supported by the observation that
neither MBP11-A-12 nor MBP11-12 could mediate adhe-
sion of HT1080 cells (data not shown). These results,
taken together, indicate that the EDA segment is unlikely
to be directly involved in enhanced cell adhesion onto the
EDA1 FN-coated substrates as an independent cell-inter-
active site.
In support of this conclusion, function-blocking mAbs
directed against the integrin a5 or b1 subunits inhibited
spreading of HT1080 cells onto the rFN(AC)-coated sub-
strates almost completely, whereas the mAbs directed
against other types of FN-binding integrins, i.e., anti-a4
and anti-avb3 mAbs, were barely inhibitory (Fig. 6).
These results indicated that spreading of HT1080 cells
onto rFN(AC)-coated substrates was predominantly me-
diated by interaction of integrin a5b1 with CCBD, as was
the case with spreading onto plasma FN-coated substrates
(Aota et al., 1991). This conclusion was further supported
by the observation that GRGDSP peptide, but not GRGESP,
inhibited almost completely rFN(AC)-mediated spreading
of HT1080 cells (Fig. 6). These results, together with the
failure of EDA antagonists to inhibit rFN(AC)-mediated
cell spreading, indicated that the EDA segment augments
the cell-adhesive activity of FNs by promoting the interac-
tion of integrin a5b1 with the RGD-containing CCBD and
not by providing an additional cell-interactive site.
Enhanced Cell Adhesive Activity of EDA1 FN Is 
Independent of Cell Surface Heparan Sulfate
Interaction of the heparin-binding domain of FN with cell
Figure 4. Dose dependence of the spreading of HT1080 cells on
recombinant FNs. HT1080 cells were seeded on plates coated
with various concentrations of rFN(C) (open circles), rFN(AC)
(closed circles), or rFN(BAC) (closed squares) and incubated for
30 min at 378C. Spreading of HT1080 cells was quantified as de-
scribed in Materials and Methods and expressed as the number of
cells adopting a well spread morphology per square millimeter.
Each bar represents the mean 6 SD (n 5 3).
Figure 5. Effects of anti-EDA mAbs and recombinant EDA
fragments on cell spreading mediated by recombinant FNs. (A)
Microtiter plates precoated with 5 mg/ml of rFN(C) (open bars)
or rFN(AC) (closed bars) were treated with the following mAbs
(20 mg/ml) at 378C for 30 min before the addition of HT1080 cells:
None, no addition of mAbs; IST-9 and HHS-01, two different
anti-EDA mAbs; FN12-81FN30-8, a mixture of two function-
blocking mAbs directed to CCBD. The cells were incubated at
378C for 30 min and the number of cells adopting a well spread
morphology was determined. (B) In separate experiments,
HT1080 cells were seeded onto microtiter plates precoated with 5
mg/ml of rFN(C) (open bars) or rFN(AC) (closed bars) and incu-
bated for 30 min at 378C in the presence or absence of MBP fu-
sion fragments with (MBP11-A-12) and without (MBP-11-12) the
EDA segment. Each bar represents the mean 6 SD (n 5 6).
Manabe et al. Functional Modulation of Fibronectin by EDA Segment 301
surface heparan sulfate has been shown to promote inte-
grin a5b1-mediated cell spreading on FN-coated sub-
strates (Woods et al., 1986). To examine the possible in-
volvement of surface heparan sulfate in enhanced cell
spreading onto EDA1 FN-coated substrates, HT1080 cells
were treated with heparitinase I before incubation on FN-
coated substrates. FACS® analysis using the anti-heparan
sulfate mAb HepSS-1 showed that .95% of heparan sul-
fate on the cell surface was removed by heparitinase treat-
ment (data not shown). The removal of surface heparan
sulfate, however, did not significantly affect the spreading
of HT1080 cells on substrates coated with either rFN(AC)
or rFN(C) (Fig. 7). A similar result was obtained when
CHO803 cells that are deficient in surface heparan sulfate
(Esko et al., 1988) were used for the cell spreading assay
(data not shown), confirming that cell surface heparan sul-
fate is apparently not involved in enhanced cell spreading
seen on rFN(AC)-coated substrates.
Increased Affinity of Integrin a5b1 to EDA1 FN
The results described above left us with the possibility that
the binding affinity of integrin a5b1 to CCBD could be en-
hanced by inclusion of the EDA segment. To explore this
possibility further, integrin a5b1 purified from human pla-
centa and reconstituted into phosphatidylcholine lipo-
somes containing [3H]dipalmitoyl phosphatidylcholine
was tested for its binding avidity to recombinant FNs with
or without the EDA segment. As depicted in Fig. 8, inte-
grin a5b1 liposomes bound to rFN(AC) significantly more
avidly than to rFN(C). Binding of integrin a5b1 liposomes
to rFN(AC) was blocked by the anti-integrin a5 mAb 8F1,
as was the case with the binding to rFN(C). No significant
binding was observed with vitronectin, confirming that the
purified a5b1 used in this study was devoid of other inte-
grins capable of binding to both FN and vitronectin (i.e.,
avb3, avb5, avb6, and aIIbb3).
Binding of integrin a5b1 to FN has been shown to de-
pend on both the RGD motif in the III10 module and the
synergy site in III9 (Aota et al., 1991). Thus, enhanced
binding of integrin a5b1 to rFN(AC) could conceivably be
due to increased affinity of the integrin to either the RGD
motif or the synergy site. To examine which site was re-
sponsible for the enhanced affinity of rFN(AC) towards
a5b1, association of integrin avb3 with rFN(AC) or
rFN(C) was examined. Binding of avb3 to FN has been
shown to depend on the RGD motif in the III10 module,
but not on the synergy site in the III9 module (Danen et
al., 1995). Integrin avb3 purified from placenta and recon-
stituted in liposomes bound more avidly to rFN(AC) than
to rFN(C), as was the case with a5b1 (Fig. 9). The binding
was reproducibly inhibited by the anti-avb3 mAb LM609
and by GRGDSP peptide, but not by the anti-a5 mAb 8F1
or the control GRGESP peptide. Residual binding of
avb3-liposomes to rFN(AC) in the presence of LM609
could result from the presence of avb5, another vitronec-
tin-binding integrin, in the purified avb3 preparation.
These results are consistent with the model that enhanced
binding of integrin a5b1 to EDA1 FN is due to an increase
in the affinity of a5b1 for the RGD motif in CCBD and
that this increased affinity may result from an altered con-
formation or accessibility of CCBD in the presence of the
EDA segment.
EDA-mediated Enhancement of Integrin Binding Is 
Not Observed with FN Fragments
The EDA segment may alter the conformation of CCBD
Figure 6. Inhibition by anti-integrin mAbs and synthetic peptides
of cell spreading mediated by recombinant FNs. HT1080 cells
were seeded on microtiter plates precoated with 5 mg/ml of
rFN(C) (open bars) or rFN(AC) (closed bars) in the presence or
absence of 10 mg/ml of the following anti-integrin mAbs or 1 mg/
ml of synthetic peptides (GRGDSP and GRGESP), and incu-
bated for 30 min at 378C: None, no mAb added; 8F1, anti-a5
mAb; 4G2, anti-b1 mAb; ST/73, anti-a4 mAb; LM609, anti-avb3
mAb. The cell spreading was quantified as described in Materials
and Methods. Each bar represents the mean 6 SD (n 5 6).
Figure 7. Effect of glycosidase treatments on spreading of
HT1080 cells on recombinant FNs. HT1080 cells were treated
with 0.1 U/ml of heparitinase I, heparinase, or chondroitinase
ABC for 30 min at 378C. Glycosidase-treated cells were added to
microtiter plates precoated with 5 mg/ml of rFN(C) (open bars) or
rFN(AC) (closed bars) and incubated for 30 min at 378C. Cell
spreading was quantified as described in Materials and Methods.
Each bar represents the mean 6 SD (n 5 6).
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by two possible mechanisms. In one model, the EDA seg-
ment inserted between the III11 and III12 modules may in-
duce steric distortion of its neighboring modules, i.e., III11
and III12, by readjusting the intermodular interfaces, which
in turn affects the conformation of adjacent modules includ-
ing RGD-containing III10. Alternatively, insertion of the
EDA segment may alter the global conformation of the
FN molecule by twisting the NH2-terminal two-thirds of
the molecule. Adjacent type III modules have been shown
to be interconnected with rotations along the long axis, of-
ten in a pseudotwofold relationship (Huber et al., 1994;
Leahy et al., 1996). To test these two possibilities, we ex-
amined binding affinities of recombinant FNs for integrin
a5b1 before and after limited proteolysis with thermol-
ysin. Under the conditions employed (Sekiguchi et al.,
1985), the central region of the FN molecule including
CCBD and the adjacent Hep2 domain was released by
thermolysin as 150–120-kD fragments from rFN(C) and as
160–130-kD fragments from rFN(AC) (data not shown).
The integrin-binding activity of rFN(C) was significantly
increased after limited proteolysis, reaching a level compa-
rable to that of rFN(AC) after thermolysin digestion (Fig.
10 A). It was also noted that the integrin-binding activity
of rFN(AC) was slightly decreased after limited proteoly-
sis. These results do not fit with the first possibility based
on the neighboring effects of the inserted EDA segment
on the III10 module but rather support the second model
that insertion of the EDA segment potentiates integrin
binding to CCBD by altering the global conformation of
the FN molecule, thereby either increasing integrin acces-
sibility to CCBD or optimizing the local conformation of
the RGD-containing III10 module by perturbing the con-
straints applied to CCBD.
To explore the second possibility further, we expressed
in bacteria recombinant FN fragments containing CCBD
and the Hep2 domain with or without the inserted EDA
segment and examined their binding to purified integrin
a5b1. Integrin a5b1 bound equally well to both recombi-
nant CCBD-Hep2 fragments with and without the EDA
segment (designated GST-CH and GST-CAH; Fig. 10 B).
The integrin binding to these fragments was completely in-
hibited by the anti-integrin a5 mAb 8F1, confirming the
specificity of this binding assay. The recombinant CCBD-
Hep2 fragments with and without the EDA segment were
also equally active in promoting spreading of HT1080 cells
(data not shown). These results provide further support
for the conclusion that the EDA segment upregulates the
integrin binding activity of CCBD through alteration of
global conformation of the FN molecule (see Discussion).
It should also be noted that no significant difference was
detected in the integrin-binding activities of recombinant
CCBD fragments with and without the Hep2 domain, indi-
cating that the binding of CCBD to integrin a5b1 is inde-
pendent of the adjacent Hep2 domain.
EDA1 FN Is More Active than EDA2 FN in 
Promoting Cell Migration
FN is known to promote cell migration via interaction with
integrin a5b1 (Yamada et al., 1990). Increased binding
avidity of integrin a5b1 for EDA1 FN may, therefore,
lead to an enhanced cell motility on substratum coated
with EDA1 FN. To test this possibility, migration of
HT1080 cells on the substrates coated with EDA1 or
EDA2 FNs were compared (Fig. 11 A). HT1080 cells were
significantly more migratory on rFN(AC) and rFN(BAC)
than on rFN(C). No significant cell migration was ob-
served on substrates coated with poly-l-lysine (data not
shown). Quantitation of outward cell migration showed
that HT1080 cells migrated 1.7–2 times farther on sub-
Figure 8. Binding of integrin a5b1 to recombinant FNs. Integrin
a5b1 was purified from human placenta and reconstituted in
phosphatidylcholine liposomes as described in Materials and
Methods. The integrin a5b1-liposomes were added to microtiter
plates precoated either with 20 mg/ml of rFN(C) (open bars) or
rFN(AC) (closed bars), or with 5 mg/ml of vitronectin (hatched
bars) in the presence or absence of the anti-integrin a5 mAb 8F1
(10 mg/ml) and incubated for 6 h at room temperature. Quantities
of bound integrin a5b1 liposomes are expressed as percentage of
the total input radioactivity after subtraction of the radioactivity
bound to plates coated only with BSA. Each bar represents the
mean 6 SD (n 5 6).
Figure 9. Binding of integrin avb3 to recombinant FNs. Integrin
avb3 liposomes were added to microtiter plates precoated either
with 20 mg/ml of rFN(C) (open bars) or rFN(AC) (closed bars) or
with 5 mg/ml of vitronectin (hatched bars) in the presence or ab-
sence of the anti-integrin avb3 mAb LM609 (50 mg/ml), the anti-
integrin a5 subunit mAb 8F1 (10 mg/ml), GRGDSP peptide (1
mg/ml), or control GRGESP peptide (1 mg/ml). The binding as-
say was carried out as described in Fig. 8. Each bar represents the
mean 6 SD (n 5 6).
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strates coated with rFN(AC) or rFN(BAC) than on the
substrate coated with rFN(C) (Fig. 11 B). Cell migration
mediated by EDA1 and EDA2 FNs was inhibited by anti-
integrin a5 mAb 8F1 to a similar extent, suggesting that in-
creased cell motility on the EDA1 FNs was due to the in-
creased integrin recognition of CCBD flanked with the
EDA segment.
Discussion
Though expression of the alternatively spliced EDA and
EDB segments of FN show spacial and temporal regula-
tion during development, wound healing, and tumorigene-
sis, little is known about the function of these variable do-
mains. In the present study, we produced three different
forms of recombinant FNs differing with respect to pres-
ence or absence of the EDA and/or EDB segments and
compared their adhesive functions using homogeneous
proteins. Our results showed that recombinant FNs con-
taining the EDA segment were approximately twice as po-
tent as those lacking EDA in their abilities to promote cell
adhesion and migration, irrespective of the presence or ab-
sence of another variable domain, EDB. The binding affin-
ity of EDA1 FN to its integrin receptor, a5b1, was 2–2.5
times greater than that of EDA2 FN, indicating that alter-
native splicing at the EDA region regulates the binding af-
finity of FNs to integrin a5b1, thereby contributing to reg-
ulation of cell adhesion and migration on FN-containing
extracellular matrices.
Functions of alternatively spliced EDA and EDB seg-
ments have been extensively studied by comparing the bi-
ological activities of the two forms of naturally occurring
FNs, i.e., plasma and cellular FNs, only the latter of which
contains substantial quantities of the EDA and/or EDB
segments. Although plasma and cellular FNs differ in cer-
tain molecular properties such as posttranslational modifi-
cation (Fukuda et al., 1982; Paul and Hynes, 1984) and sol-
ubility (Yamada et al., 1977), no significant differences
have been found in their cell-adhesive activities (Yamada
and Kennedy, 1979). Failure to detect differences in their
adhesive properties could be due to heterogeneity of cellu-
lar FN used in earlier studies. Typically, cellular FN ex-
pressed in cultured fibroblasts contains as much as 50% of
EDA2 isoforms (Magnuson et al., 1991), leaving only 25%
of the entire dimer population as EDA1 homodimers pro-
vided that dimerization of different forms of FN polypep-
tides occurs stochastically. In contrast, recombinant FNs
used in this study were homogeneous in terms of the pres-
ence or absence of the EDA and/or EDB segments, allow-
ing us to demonstrate clearly enhanced cell-adhesive activ-
ity of EDA1 FN isoforms.
Previously, Guan et al. (1990) reported expression and
isolation of various forms of rat recombinant FNs. Com-
parison of the cell-adhesive activity of these recombinant
FNs, however, showed no difference between EDA1 and
EDA2 isoforms. The apparent discrepancy between this
report and our present study could be due to the differ-
ence in the molecular structure of the recombinant FNs
used. The EDA1 FN used by Guan et al. (1990) did not
contain the IIICS segment, whereas isoforms tested in the
present study all included the complete IIICS segment,
which has been shown to be critical for secretion of dimer-
ized nascent FN polypeptides (Schwarzbauer et al., 1989).
The EDA1 form of rat FN used by Guan et al. (1990) was
predominantly secreted as monomer, whereas rFN(AC)
used in the present study was secreted as dimer. It is possi-
ble that the IIICS region may be required for EDA-
dependent potentiation of the cell-adhesive activity of FNs
by ensuring dimer formation or rendering the FN mole-
cule competent for conformational activation upon inser-
tion of the EDA segment (see below).
Several lines of evidence indicate that the EDA segment
enhances the cell-adhesive activity of FNs by increasing
binding affinity to integrin a5b1 and not by providing an
additional cell-adhesive site. Thus, function-blocking mAbs
against CCBD or those against integrin a5b1 inhibited
rFN(AC)-mediated cell spreading almost completely, while
mAbs against the EDA segment showed no inhibition.
Consistent with these observations, rFN(AC)-mediated
cell spreading was also completely inhibited by GRGDSP
peptide but not by the EDA-containing recombinant frag-
ment. Enhanced binding affinity of EDA1 FN to integrin
Figure 10. Binding of integrin a5b1 to
FN fragments. (A) Microtiter plates
were coated with 20 mg/ml of rFN(C)
(open bars) or rFN(AC) (closed bars)
that had been digested with thermol-
ysin for 0 min (Undigested) and 10 min
(Digested) as described in Materials
and Methods. The plates were incu-
bated with integrin a5b1 reconstituted
in phosphatidylcholine liposomes for 6 h
at room temperature. Quantities of
bound integrin a5b1 liposomes were
expressed as percentages of the total in-
put radioactivity after subtraction of
the radioactivity bound to plates coated
only with BSA. Each bar represents the
mean 6 SD (n 5 3). (B) Microtiter
plates were coated with 20 mg/ml (open bars) or 80 mg/ml (closed and hatched bars) of GST fusion proteins containing the CCBD alone
(GST-C) or both the CCBD and the Hep2 domain with (GST-CAH) or without (GST-CH) the EDA segment. Integrin a5b1 liposomes
were added to the plates and incubated for 6 h at room temperature in the absence (open and closed bars) or presence (hatched bars) of
the anti-integrin a5 mAb 8F1 (10 mg/ml). Each bar represents the mean 6 SD (n 5 6).
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a5b1 was demonstrated by a direct binding assay using in-
tegrin a5b1 purified and reconstituted into liposomes.
Previously, Xia and Culp (1994, 1995) reported that a
recombinant EDA segment alone or in combination with
its neighboring type III modules promoted adhesion of
mouse 3T3 cells. The recombinant EDA segment was also
reported to transform rat lipocytes into myofibroblasts
(Jarnagin et al., 1994). These observations may suggest the
presence of a specific cell surface receptor for the EDA
segment, although the molecular identity of the receptor
remains elusive. Despite these previous reports, we could
not obtain evidence to support direct interaction of the
EDA segment with cells. Our MBP fusion protein consist-
ing of III11, EDA, and III12 modules did not have an activ-
ity to mediate cell attachment or spreading. Although the
reason for this discrepancy remains to be clarified, the pu-
tative EDA receptor(s) could be expressed only in limited
types of cells (e.g., 3T3 cells). It may also be possible that a
tag of histidine hexamer added to the recombinant EDA
fragment (Xia and Culp, 1994, 1995) could potentiate the
interaction of the EDA segment with putative EDA re-
ceptor(s).
Recently, Hino et al. (1996) reported that EDA-enriched
cellular FN was more potent than plasma FN in promoting
adhesion of human synovial cells. Adhesion of synovial
cells to EDA-enriched FN was partially inhibited by anti-
Hep2 mAb and also by heparitinase treatment of the cells,
suggesting that insertion of the EDA segment may en-
hance the cell-adhesive activity of FN by potentiating the
interaction of the Hep2 domain with cell surface heparan
sulfate proteoglycans. Despite these observations, our re-
sults showed that the interaction of the Hep2 domain with
heparan sulfate proteoglycans was not involved in the en-
hanced adhesion of HT1080 cells on EDA1 FN-coated
substrates, since (a) heparitinase treatment did not affect
cell spreading onto rFN(AC)-coated substrates; (b) gly-
cosaminoglycan-deficient CHO cells were fully competent
to reproduce the difference in the cell spreading activity
seen between rFN(AC) and rFN(C); (c) none of the mAbs
directed to the Hep2 domain inhibited adhesion of HT1080
cells to rFN(AC)-coated surfaces (Manabe, R., unpub-
lished observation). Although the reason for this discrep-
ancy is not clear, the role of the Hep2 domain in EDA1
FN-mediated cell adhesion may differ among different cell
types, synovial cells being strongly dependent on the inter-
action of the Hep2 domain with heparan sulfate proteogly-
cans. Since the inhibition of synovial cell adhesion by anti-
Hep2 mAb and by heparitinase treatment was only partial
(Hino et al., 1996), it is likely that enhanced integrin bind-
ing due to the inserted EDA segment was also involved in
increased synovial cell adhesion onto EDA-enriched FN.
There are several possible mechanisms that may explain
enhanced integrin-binding affinity of EDA1 FNs. First,
the EDA segment might directly interact with integrins
a5b1 and avb3, thereby synergizing with the binding of
the RGD motif to these integrins (ffrench-Constant,
1995). This possibility seems unlikely, however, since bind-
ing of integrin a5b1 to the GST-fusion protein consisting
of CCBD and the Hep2 domain was not affected by the
presence or absence of the EDA segment. A second possi-
bility is that insertion of the EDA segment alters the con-
formation of the neighboring type III modules including
Figure 11. Migration of HT1080 cells on recombinant FNs. 96-
well plates were precoated with 5 mg/ml of rFN(C) (open bars),
rFN(AC) (closed bars), or rFN(BAC) (hatched bars) and then
partially covered with plastic discs (f 6 mm) that had been cut in
half and coated with 0.01% poly-l-lysine. HT1080 cells were
seeded onto the plates and incubated for 1.5 h at 378C to allow
them to spread. The plastic discs were then removed and the cells
were further incubated at 378C for 12 h to allow them to migrate
into the open space left after removal of the discs. (A) The cells
were photographed before and after migration at 378C for 12 h.
The positions of the cell front before and after the cell migration
were indicated by open and closed arrowheads, respectively. (B)
Cell motility on different substrates was quantified by measuring
the distance of outward migration, i.e., the distance between the
positions of the cell front before and after cell migration. Cell
motility was assayed in the presence or absence of 20 mg/ml of the
anti-integrin a5 subunit mAb 8F1 or control IgG. Each bar repre-
sents the mean 6 SD (n 5 6).
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III10, thereby enhancing the integrin-binding affinity of
CCBD (ffrench-Constant, 1995). Analyses of the three-
dimensional structure of a recombinant FN fragment con-
sisting of III7–III10 modules revealed that two adjacent
type III modules are interconnected with tilts and rota-
tions along the long axis (Leahy et al., 1996). Insertion of
an extra type III module (i.e., the EDA module) could al-
ter the conformation of the neighboring modules (i.e., III11
and III12) by readjusting the intermodular rotations and
tilts, which could in turn alter the conformation of their
neighboring modules including III10 so as to optimize the
conformation of the RGD-containing loop. The third pos-
sibility is that insertion of the EDA segment alters the glo-
bal conformation of the FN molecule by rotating the NH2-
terminal portion of the FN polypeptide relative to the
COOH terminus (Fig. 12). Given a pseudo-twofold rela-
tionship between adjacent type III modules (Huber et al.,
1994; Leahy et al., 1996), the insertion of the EDA seg-
ment is expected to rotate the NH2-terminal two-thirds
(the NH2 terminus through III11) up to 1808 relative to the
COOH-terminal one-third (III12 through the COOH ter-
minus). Such a change in global conformation may not
only increase the accessibility of the RGD motif in CCBD
to the integrins a5b1 and avb3 but also induce partial un-
folding of the III10 module by altering the tension and/or
torsion applied to CCBD. Our results obtained with ther-
molysin-cleaved recombinant FNs and GST fusion pro-
teins consisting of CCBD and the Hep2 domain clearly
showed that enhanced integrin-binding of EDA1 FN was
only observable in the context of the intact FN molecule,
consistent with the third possibility. The significant in-
crease in the integrin-binding affinity of EDA2 FN after
limited proteolysis suggests that the integrin binding site
of EDA2 FN is either partially cryptic in the intact mole-
cule or folded into a conformation with suboptimal affinity
for integrin a5b1. In support of this notion, the binding of
plasma FN to hamster kidney cells has been reported to
increase up to twofold after tryptic digestion (Hayashi and
Yamada, 1983; Akiyama et al., 1985). It should also be
noted that the integrin-binding activity of EDA1 FN was
slightly decreased after limited proteolysis, suggesting that
conformational change induced by the inserted EDA seg-
ment not only increases the exposure of the integrin-bind-
ing site on the surface of the FN molecule but also per-
turbs the local conformation of CCBD, particularly the
RGD-containing III10, to optimize the affinity for integrin
a5b1. In support of this possibility, the FN type III mod-
ules have been proposed to undergo reversible unfolding
with a relatively weak force that is comparable to that re-
quired to dissociate a noncovalent protein–protein inter-
action (Erickson, 1994).
Accumulating evidence indicates that the strands of the
FN molecule are folded into a compact shape under physi-
ological buffer conditions and undergo conformational
transitions from a compact to an extended form in solu-
tions of high ionic strength or high pH (Williams et al.,
1982; Erickson and Carrell, 1983). Such conformational
transitions have also been observed in monomeric forms
of FN subunits produced by reduction and subsequent car-
boxyamidomethylation of disulfides or by limited proteol-
ysis (Erickson and Carrell, 1983; Benecky et al., 1990), in-
dicating that the FN strands are folded into a compact
structure by an intra-chain interaction (although involve-
ment of an inter-chain interaction can not be rigorously
excluded). Although the regions involved in intra- and/or
inter-chain interaction have not been fully elucidated, the
III1 module may play an important role. The III1 module
was reported to bind multiple regions in FN including the
NH2-terminal 70-kD region, the III10 module, and the
COOH-terminal fibrin-binding domain (Aguirre et al.,
1994; Hocking et al., 1996; Ingham et al., 1997). It is tempt-
ing to speculate that EDA-mediated rotation of the NH2-
terminal two-thirds relative to the COOH terminus redi-
rects intra- and/or inter-chain interactions, resulting in
transition of the global conformation of the FN molecule
from one state to another (Fig. 12).
The proposed EDA-induced change in the global con-
formation of FN is further supported by the following dis-
tinctions between the EDA1 and EDA2 FN isoforms.
Cellular FN containing EDA and/or EDB segments has
been shown to be much less soluble than plasma FN under
physiological buffer conditions (Yamada et al., 1977). Altered
solubility can be easily explained by changes in global con-
formation that may increase the exposure of hydrophobic
and/or charged surfaces of the FN molecule. Furthermore,
alteration in global conformation may be compatible with
an increased matrix assembly of the EDA1 FN isoforms.
Guan et al. (1990) reported that EDA1 isoforms were
Figure 12.  A schematic model
for EDA-induced conforma-
tional change of FN. The FN
molecule is folded into a
compact conformation due
to intra- and/or inter-chain
interactions. Insertion of the
EDA segment (black) be-
tween CCBD (gray) and the
Hep2 domain rotates the
NH2-terminal region encom-
passing the NH2 terminus
through the III11 module up
to 1808C relative to the re-
gion COOH-terminal to the
inserted EDA segment, leading to a change in the global conformation of the FN molecule. Such a conformational change may increase
the accessibility of the RGD motif within CCBD to integrin a5b1 and/or alter the local conformation of the III10 module so as to opti-
mize the binding of integrin a5b1 to the RGD motif. Arrowheads point to the position of the EDA insertion.
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more readily incorporated into the extracellular matrix
than an isoform lacking both EDA and EDB segments. We
also found that rFN(AC) is 2–3-fold more efficient than
rFN(C) in assembling into the extracellular matrix (Manabe,
R., unpublished observation). Although the molecular
mechanisms for FN matrix assembly remain to be eluci-
dated, FNs are considered to undergo a conformational
change from a compact to an extended conformation upon
binding to integrin receptors on cell surfaces, thereby dis-
sociating intramolecular interactions and exposing sites
for FN–FN interaction (Mosher, 1993; Sechler et al., 1996).
The EDA-mediated conformational change may acceler-
ate FN matrix assembly by facilitating the conformational
activation of FNs upon binding to RGD-dependent inte-
grins, particularly a5b1.
In vivo expression patterns of different FN isoforms sug-
gest a role for EDA1 FN in cell growth as well as in cell
migration. The EDA segment is included in FN species ex-
pressed in embryonic tissues but is spliced out of the mole-
cule in most tissues as embryonic development progresses
(Vartio et al., 1987; ffrench-Constant and Hynes, 1989). In
adults, EDA1 FNs reappear during wound healing and in
tumor tissues (ffrench-Constant et al., 1989; Oyama et al.,
1989a). In addition, levels of the EDA1 FN expression are
significantly higher in invasive tumors than in noninvasive
ones (Oyama et al., 1989a). Since tissues where EDA1
FNs are highly expressed are populated with cells having
high proliferative and migratory potentials, it seems likely
that EDA1 FNs play an important role in promoting cell
proliferation and migration in vivo. In support of this no-
tion, our results show that EDA1 FN is more potent than
EDA2 FN in promoting migration of HT1080 cells. Under
circumstances where vast cell proliferation and migration
are required, the splicing pattern at the EDA region is ap-
parently altered to produce more EDA1 FN isoforms and,
in so doing, to strengthen signals from the surrounding FN
matrix. Regulation of extracellular signals at the level of
RNA splicing represents a novel mechanism for the con-
trol of proliferation, differentiation, and apoptosis of ad-
herent cells.
Despite the importance of the EDA segment in regulating
the cell-adhesive properties of FN, the function of the EDB
segment remains to be defined. Since expression of EDB1
FN isoforms in vivo is more restricted than that of EDA1
isoforms (ffrench-Constant and Hynes, 1989), the EDB
segment may have an important function only in highly
specific situations, such as early embryonic development.
By analogy with the EDA segment, the insertion of the
EDB segment is expected to alter the global conformation
of the FN molecule by rotating the NH2-terminal half (i.e.,
NH2 terminus through III7) relative to the COOH termi-
nus. Although the EDB segment did not affect the cell-
adhesive activity of EDA1 FNs, it may modulate other
biological functions of FN through conformational pertur-
bation. Further studies on the biological activities of a
panel of recombinant FN isoforms differing with respect
to presence or absence of EDA and EDB segments should
provide clues to the function of the EDB segment.
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